Immutep Announces Positive Final Data in 2nd Line Metastatic NSCLC Patients Refractory to Anti-PD-(L)1 Therapy at European Lung Cancer Congress 2023
Media Release Efti plus pembrolizumab achieved mOS of 9.9 months and a 39% OS rate…
Year: 2023
Immutep Announces Positive Final Data in 2nd Line Metastatic NSCLC Patients Refractory to Anti-PD-(L)1 Therapy at European Lung Cancer Congress 2023
Media Release Efti plus pembrolizumab achieved mOS of 9.9 months and a 39% OS rate…
NewAmsterdam Pharma Reports Full Year 2022 Financial Results and Provides Corporate Update
— Completed business combination with FLAC and closed concurrent, oversubscribed approximately $235 million PIPE, led…
NewAmsterdam Pharma Reports Full Year 2022 Financial Results and Provides Corporate Update
— Completed business combination with FLAC and closed concurrent, oversubscribed approximately $235 million PIPE, led…
Novartis Entresto receives positive CHMP opinion for pediatric heart failure
If subsequently approved, Entresto will be the first and only approved therapy for the treatment…
Novartis Entresto receives positive CHMP opinion for pediatric heart failure
If subsequently approved, Entresto will be the first and only approved therapy for the treatment…
TG Therapeutics Announces Positive CHMP Opinion for BRIUMVI™ (ublituximab-xiiy) for the Treatment of Relapsing Forms of Multiple Sclerosis in Adults
NEW YORK, March 31, 2023 (GLOBE NEWSWIRE) — TG Therapeutics, Inc. (NASDAQ: TGTX), today announced that the…
TG Therapeutics Announces Positive CHMP Opinion for BRIUMVI™ (ublituximab-xiiy) for the Treatment of Relapsing Forms of Multiple Sclerosis in Adults
NEW YORK, March 31, 2023 (GLOBE NEWSWIRE) — TG Therapeutics, Inc. (NASDAQ: TGTX), today announced that the…
Bioventus Reports Fourth Quarter and Full-Year 2022 Financial Results
DURHAM, N.C., March 31, 2023 (GLOBE NEWSWIRE) — Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or “the…
Bioventus Reports Fourth Quarter and Full-Year 2022 Financial Results
DURHAM, N.C., March 31, 2023 (GLOBE NEWSWIRE) — Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or “the…
Instil Bio Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update
Instil confirms cash runway beyond 2026 ITIL-306 phase 1 study anticipated to receive CTA clearance…
Instil Bio Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update
Instil confirms cash runway beyond 2026 ITIL-306 phase 1 study anticipated to receive CTA clearance…
Bio-Path Holdings Reports Full Year 2022 Financial Results
Conference Call to be Held Today at 8:30 A.M. ET HOUSTON, March 31, 2023 (GLOBE…
Bio-Path Holdings Reports Full Year 2022 Financial Results
Conference Call to be Held Today at 8:30 A.M. ET HOUSTON, March 31, 2023 (GLOBE…
BioCryst Appoints Dr. Nancy Hutson as Chair of the Board
RESEARCH TRIANGLE PARK, N.C., March 31, 2023 (GLOBE NEWSWIRE) — BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX)…
BioCryst Appoints Dr. Nancy Hutson as Chair of the Board
RESEARCH TRIANGLE PARK, N.C., March 31, 2023 (GLOBE NEWSWIRE) — BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX)…
Disc Medicine Reports Full Year 2022 Financial Results and Provides Business Update
Completed reverse merger with Gemini Therapeutics, debuting on Nasdaq as “IRON” and ending 2022 with…
Disc Medicine Reports Full Year 2022 Financial Results and Provides Business Update
Completed reverse merger with Gemini Therapeutics, debuting on Nasdaq as “IRON” and ending 2022 with…
Bioventus Enters into an Amendment with its Credit Agreement Lenders to Enhance Financial and Operational Flexibility
DURHAM, N.C., March 31, 2023 (GLOBE NEWSWIRE) — Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or the…
Bioventus Enters into an Amendment with its Credit Agreement Lenders to Enhance Financial and Operational Flexibility
DURHAM, N.C., March 31, 2023 (GLOBE NEWSWIRE) — Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or the…